Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 20/2/2019
SIETES contiene 92669 citas

 
 
 1 a 20 de 2510 siguiente >>
Presentar resultados
Seleccionar todas
1.Enlace a cita original Cita con resumen
Cholesterol Treatment Trialists’ Collaboration. Efficacy and safety of statin therapy in older people: a meta-analysis of individual participant data from 28 randomised controlled trials. Lancet 2019;393:2 de febrero. [Ref.ID 103016]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]
3.Enlace a cita original Cita con resumen
Caughey GE, Gabb GM, Ronson S, Ward M, Beukelman T, Hill CL, Limaye V. Association of statin exposure with histologically confirmed idiopathic inflammatory myositis in an Australian population. JAMA Intern Med 2018;178:septiembre. [Ref.ID 102883]
4.Enlace a cita original Cita con resumen
Richman IB, Ross JS. Weighing the harms and benefits of using statins for primary prevention: raising the risk threshold. Ann Intern Med 2018:4 de diciembre. [Ref.ID 102877]
5.Enlace a cita originalTiene citas relacionadas Cita con resumen
Samper E. Así influyen las farmacéuticas sobre los médicos . eldiario.es 2018:18 de octubre. [Ref.ID 102834]
6.Enlace a cita original Cita con resumen
Comoretto RI, Rea F, Lucenteforte E, Mugelli A, Trifirò G, Cascini S, Roberto G, Chinellato A, Filippelli A, Corrao G, on behalf of the Italian Group for Appropriate Drug prescription in the Elderly (I-GrADE). Bleeding events attributable to concurrent use of warfarin and other medications in high-risk elderly: meta-analysis and Italian population-based investigation. Eur J Clin Pharmacol 2018;74:1061-70. [Ref.ID 102823]
8.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navarese EP, Robinson JG, Kowatewski M, Kotodziejczak M, Andreotti F, Bliden K, Tantry U, Kubica J, Raggi P, Gurbel PA. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering. A systematic review and meta-analysis. JAMA 2018;319:17 de abril. [Ref.ID 102784]
9.Enlace a cita originalTiene citas relacionadas Cita con resumen
Navar AM, Peterson ED. Challenges in interpreting the lipid-lowering trials: biology vs ecology. JAMA 2018;319:17 de abril. [Ref.ID 102783]
10.Enlace a cita original Cita con resumen
Voelker R. Another caution for clarithromycin. JAMA 2018;319:1 de junio. [Ref.ID 102782]
11.Enlace a cita original Cita con resumen
Bielecka-Dabrowa A, Fabis J, Mikhailidis DP, von Haehling S, Sahebkar A, Rysz J, Banach M. Prosarcopenic effects of statins may limit their effectiveness in patients with heart failure. Trends Pharmacol Sci 2018;39:abril. [Ref.ID 102681]
12.Enlace a cita original Cita con resumen
Yadlowsky S, Hayward RA, Sussman JB, McClelland RL, Min YI, Basu S. Clinical implications of revised pooled cohort equations for estimating atherosclerotic cardiovascular disease risk. Ann Intern Med 2018;169:20-9. [Ref.ID 102647]
13. Cita con resumen
Maier L, Pruteanu M, Kuhn M, Zeller G, Telzerow A, Anderson EE, Brochado AR, Fernandez KC, Dose H, Mori H, Patil KR, Bork P, Typas A. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 2018;555:29 de marzo. [Ref.ID 102577]
14.Enlace a cita original Cita con resumen
Golomb BA, Verden A, Messner AK, Koslik HJ, Hoffman KB. Amyotrophic lateral sclerosis associated with statin use: a disproportionality analysis of the FDA's adverse event reporting system. Drug Saf 2018;41:abril. [Ref.ID 102565]
15.Enlace a cita original Cita con resumen
Garattini S, Bertele V. Benefits, benefits, once more benefits... with no risk? Stop overlooking the harms of medicines. Eur J Clin Pharmacol 2018;74:marzo. [Ref.ID 102550]
16.Tiene citas relacionadas Cita con resumen
Diamond D, Kendrick M, Mascitelli L. Exaggerated report of benefits in a flawed long term statin treatment study. BMJ 2017;359:j4915. [Ref.ID 102120]
17.Tiene citas relacionadas Cita con resumen
Ravnskov U, Okuyama H, Sultan S. Serious bias in 20 year follow-up study of statin trial. BMJ 2017;359:j4906. [Ref.ID 102119]
18. Cita con resumen
Hawkes N. Statin initiation is unrelated to cardiovascular risk score, finds study.. BMJ 2017;359:j4898. [Ref.ID 102110]
19.Enlace a cita original Cita con resumen
Crandall JP, Mather K, Rajpathak SN, Goldberg RB, Watson K, Foo S, Ratner R, Barrett-Connor E, Temprosa M, on behalf of the Diabetes Prevention Program(DPP) Research Group. Statin use and risk of developing diabetes: results from the Diabetes Prevention Program.. BMJ Open Diabetes Research & Care 2017;5:1-10. [Ref.ID 102101]
20. Cita con resumen
Quinn KL, Macdonald EM, Mamdani MM, Diong C, Juurlink DN, for the Canadian Drug Safety and Effectiveness Research Network (CDSERN). Lipophilic statins and the risk of intracranial hemorrhage following ischemic stroke: a population-based study. Drug Saf 2017;40:887-93. [Ref.ID 102077]
Seleccionar todas
 
 1 a 20 de 2510 siguiente >>